This article has Open Peer Review reports available.
Duodenal somatostatinoma: a case report and review of the literature
© Koc et al.; licensee BioMed Central Ltd. 2013
Received: 15 July 2012
Accepted: 8 March 2013
Published: 25 April 2013
About 70% of well-differentiated endocrine tumors arise from the gastrointestinal tract. Duodenal well-differentiated endocrine tumors account for only 2.6% of all neuroendocrine tumors. Following the first two case reports of somatostatin-secreting tumors in 1977, fewer than 200 cases of somatostatinoma have been reported. These tumors of the duodenum are usually silent and asymptomatic, but can cause gastrointestinal symptoms. Depending on the localization of the tumor, multiple surgical procedures can be performed, ranging from local resection to pancreaticoduodenectomy.
Here, we report a case of a submucosal duodenal mass in a 42-year-old Turkish White man presenting with nausea, vomiting, fatigue and abdominal pain. The treatment decision of pancreaticoduodenectomy made preoperatively was later altered to intraoperative removal via local resection with sphincteroplasty.
Tumors of the periampullary region are considered highly malignant, and the Whipple operation is usually the only procedural treatment. In the current case, we decided not to perform pancreaticoduodenectomy but to excise the mass intraoperatively, and consequently avoided unnecessary resection of the pancreas and anastomosis to undilated hepatic and pancreatic ducts. This protective strategy prevented duodenum- and pancreas-related morbidity.
KeywordsNeuroendocrine Pancreaticoduodenectomy Somatostatinoma
Carcinoid tumors of the duodenum are usually hormonally silent endocrine cell tumors. Langhans is often credited with the first description of a gut carcinoid tumor in 1867 . Gastroenteropancreatic endocrine tumors are rare neoplasms, with one to four cases documented per 100,000 people each year . Since the first two case reports of somatostatin-secreting tumors in 1977, fewer than 200 cases of somatostatinoma have been reported . Classification of neuroendocrine tumors (NETs) of the duodenum is based on hormone production, for instance, carcinoid (serotonin), somatostatinoma, or gastrinoma, because each induces a distinct clinical syndrome. About 70% of well-differentiated endocrine tumors (WDET) arise from the gastrointestinal tract . Duodenal WDETs account for only 2.6% of all NETs [5, 6]. Ileal NETs and/or carcinoids are frequently located in the small bowel (>70%), but recent studies have shown that NETs of the duodenum are more commonly encountered (22%) . Somatostatin-producing tumors also give rise to the somatostatin syndrome, which was initially reported by Krejs et al. in 1979 . Typical somatostatin syndrome comprises the triad of diabetes mellitus, cholelithiasis, and steatorrhea . These tumors can be excised using invasive or noninvasive procedures, depending on their localization.
In our case, because histopathologic findings were insufficient and unconfirmed preoperatively, a pancreaticoduodenectomy was planned, but after intraoperative exploration, the mass was thought to be a NET and resected locally, with frozen section examination showing malignancy-free margins. Neuroendocrine cell tumors should always be considered if found in the periampullary region, as in our case. Here, we have reported a case of nonfunctional duodenal somatostatinoma showing regional lymph node and sphincter of Oddi metastases, and reviewed the literature focusing on the latest clinical outcomes of this disease.
Carcinoid tumors of the duodenum are generally low-grade NETs. The term ‘neuroendocrine’ is derived based on similarities between these cells and neural cells in terms of expression of specific proteins, such as synaptophysin, neuron-specific enolase and chromogranin A . These tumors arise from enterochromaffin cells of the gastrointestinal tract. The gastrointestinal tract contains at least 14 different endocrine cell types, including enterochromaffin cells that are classically associated with carcinoid tumors . In the duodenum, most NETs are nonfunctional, sporadic, well differentiated and slow growing . Ultimately, 22% of all NETs of the small bowel arise from the duodenum . Duodenal carcinoids are most common in the proximal duodenum and present as early enhancing intraluminal polyps or mural masses . The symptoms usually consist of abdominal complaints, such as pain, nausea, vomiting and bleeding. The majority of patients do not display distant organ metastases. For duodenal somatostatinomas, the somatostatin syndrome can occur only if the tumor is larger than 4cm . Somatostatin is a cyclic tetradecapeptide secreted by the hypothalamus, cerebrum, spinal cord, vagus nerve, and D cells in Langerhans islets of the pancreas, stomach, duodenum, and small intestine.
In our patient, the tumor originated from the third portion of the duodenum and was measured as 1.7cm. The patient presented with nonspecific gastrointestinal symptoms, such as abdominal pain, fatigue, nausea and vomiting. The serum insulin, glucagon, gastrin, somatostatin and urine 5-hydroxyindoleacetic acid levels were not assessed because the mass was not considered a NET preoperatively. Histopathologically, a characteristic structure is the psammoma body, which has been identified in 68% of duodenal somatostatinomas . On silver staining, the majority of carcinoid tumors are argyrophilic, but seldom argentaffinic . The tumor characteristics of our patient were consistent with those of somatostatinoma. Gastrointestinal NETs appear at all ages, with the highest incidence recorded from the fifth decade upwards . NETs of the stomach, duodenum, appendix or rectum are small (≤1cm) and well differentiated; they are considered ‘early’ tumors because they generally have very good prognosis . In the new World Health Organization classification of 2010, these neoplasms are grouped as grade 1 or 2 NETs and/or carcinoids (NETs), and distinguished from poorly differentiated NECs, G3. Duodenal carcinoids are usually detected at the early and treatable stages as a result of considerable progress in the latest imaging techniques. Using these techniques, even very small lesions can be diagnosed. The general widespread use of gastrointestinal endoscopy has led to a shift in the discovery of smaller (≤10 to 20mm) gastrointestinal NETs and/or carcinoids at the time of diagnosis . Endoscopic ultrasound examination is highly sensitive for detecting NETs of the duodenum because it facilitates the identification of submucosal lesions and staging .
Primary surgical resection of the tumor and regional lymph nodes is the only curative treatment for gastrointestinal NETs. This is usually possible in about 20% of patients . There is a wide consensus that surgery should be recommended for tumors larger than 20mm. Unfortunately, opinion on the optimal extent of surgical treatment is divided, and therapeutic options for NETs of the duodenum that are nonfunctional, well differentiated and 10 to 20mm in size are controversial. The impact of regional lymph node metastases on survival is uncertain at present. Regardless of the primary tumor size, if abnormal lymph nodes are detected, the tumor and all the regional lymph nodes should be removed. Burke et al.  identified three pathologic features of the primary tumor as independent risk factors for metastasis: invasion of the muscularis propria, size greater than 2cm, and the presence of mitotic figures. Soga  showed that lymph node metastasis is associated with 9.8% of gastrointestinal NETs with submucosal invasion, even in cases when the tumor diameter is 1.0cm or less, suggesting that the risk of metastasis does not differ appreciably from that of carcinoma. In terms of duodenal carcinoids, even small lesions are associated with a risk of lymph node metastasis, which is related to tumor diameter and depth of invasion. In general, carcinoid tumors arising from the small intestine have the greatest propensity to metastasize, even at small sizes, compared with those in the appendix, colon and rectum . Adjuvant chemotherapy for somatostatinomas is not recommended owing to insufficient data, and palliative chemotherapy for unresectable or advanced tumors has limited benefits.
NETs of the small bowel are increasing in incidence. With access to new diagnostic and imaging techniques, detection of these tumors in the United States of America has increased by 300% to 500% in the past 35 years. Simultaneously, prognosis of these tumors has improved considerably . Data from the United States of America have revealed that the incidence of gastrointestinal NETs has increased at a rate of 3% to 10% per year over the past three decades [6, 22]. The overall 5-year survival rate for patients with gastrointestinal NETs and/or carcinoids has improved by almost 20% in the last 35 years . The overall 5-year survival rate for patients with somatostatinoma is 40% to 60% , 40% in somatostatinomas with liver metastasis, and 100% in tumors without liver or lymph node metastases .
Tumors of the periampullary region are considered highly malignant, and the Whipple operation is usually the only procedural treatment. This procedure is a pancreaticoduodenectomy, which is fairly invasive with a number of postoperative potential complications, such as pancreatic fistula, gastroparesis, and malabsorption. Overall survival after Whipple operation for pancreatic adenocarcinoma is about 20% at 5 years after surgery. However, the optimal resection extent of duodenal tumors has not been defined as yet. A number of researchers advocate pancreaticoduodenectomy  for all patients with malignant tumors of the duodenum, including those located in the third and fourth portions, to ensure adequate en bloc resection. If the tumor is an adenocarcinoma or carcinoid, en bloc resection and systemic lymph node dissection are indicated . Others support pancreaticoduodenectomy for proximal duodenal carcinoma, but segmental resection for tumors in the third and fourth portions [26–28]. In the current case, we decided not to perform pancreaticoduodenectomy but to excise the mass intraoperatively, and consequently avoided unnecessary resection of the pancreas and anastomosis to undilated hepatic and pancreatic ducts. This protective strategy prevented duodenum- and pancreas-related morbidity.
Tumors of the periampullary region are considered highly malignant, and the Whipple operation is usually the only procedural treatment. In the current case, we decided not to perform pancreaticoduodenectomy but instead to excise the mass intraoperatively, and consequently avoided unnecessary resection of the pancreas and anastomosis to undilated hepatic and pancreatic ducts. This protective strategy prevented duodenum- and pancreas-related morbidity.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Langhans T: Ueber einen drusenpolyp im ileum. Virchow Arch Pathol Anat Physiol Klin Med. 1867, 38: 559-560. 10.1007/BF02114017.View ArticleGoogle Scholar
- Taal BG, Visser O: Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004, 1 (80 Suppl): 3-7.View ArticleGoogle Scholar
- Larsson LI, Hirsch MA, Holst JJ, Ingemasson S, Kühl C, Jensen SL, Lungqvist G, Rehfeld JF, Schwartz TW: Pancreatic somatostatinoma: clinical features and physiological implications. Lancet. 1977, 1: 666-668.View ArticlePubMedGoogle Scholar
- Ishido K, Tanabe S, Higuchi K, Sasaki T, Catada C, Azuma M, Naruke A, Koizumi W, Mikami T: Clinicopathological evaluation of duodenal well-differentiated endocrine tumors. World J Gastroenterol. 2010, 16 (36): 4583-4588. 10.3748/wjg.v16.i36.4583.View ArticlePubMedPubMed CentralGoogle Scholar
- Soga J: Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: a comparative study between ordinary carcinoids and atypical varieties. J Exp Clin Cancer Res. 1998, 17: 3-12.PubMedGoogle Scholar
- Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003, 97: 934-959. 10.1002/cncr.11105.View ArticlePubMedGoogle Scholar
- Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS: Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009, 249: 63-71. 10.1097/SLA.0b013e31818e4641.View ArticlePubMedGoogle Scholar
- Krejs GJ, Orci L, Conlon JM, Ravazzola M, Davis GR, Raskin P, Collins SM, McCarthy DM, Baetens D, Rubenstein A, Aldor TA, Unger RH: Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med. 1979, 301: 285-292. 10.1056/NEJM197908093010601.View ArticlePubMedGoogle Scholar
- Tan EH, Tan CH: Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol. 2011, 2 (1): 28-43. 10.5306/wjco.v2.i1.28.View ArticlePubMedPubMed CentralGoogle Scholar
- Rindi G, Leiter AB, Kopin AS, Bordi C, Solcia E: The ‘normal’ endocrine cell of the gut. Changing concepts and new evidences. Ann NY Acad Sci. 2004, 1014: 1-12. 10.1196/annals.1294.001.View ArticlePubMedGoogle Scholar
- Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P: Site-spesific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007, 451 (Suppl 1): S9-S27.View ArticlePubMedGoogle Scholar
- Levy AD, Taylor LD, Abbott RM, Sobin LH: Duodenal carcinoids: imaging features with clinical-pathologic comparison. Radiology. 2005, 237: 967-972. 10.1148/radiol.2373041863.View ArticlePubMedGoogle Scholar
- House MG, Yeo CJ, Schulick RD: Periampullary pancreatic somatostatinoma. Ann Surg Oncol. 2002, 9: 869-874. 10.1007/BF02557523.View ArticlePubMedGoogle Scholar
- Tanaka S, Yamasaki S, Matsushita H, Ozawa Y, Kurosaki A, Takeuchi K, Hoshihara Y, Doi T, Watanabe G, Kawaminami K: Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastases. Pathol Int. 2000, 50: 146-152. 10.1046/j.1440-1827.2000.01016.x.View ArticlePubMedGoogle Scholar
- Hoffman KM, Furukawa M, Jensen RT: Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005, 19: 675-697. 10.1016/j.bpg.2005.05.009.View ArticleGoogle Scholar
- Öberg K, Åkerström G, Rindi G, Jelic S: Neuroendocrine gastroenteropancreatic tumours: ESMO clinical prtice guidelines for diagnosis. Treatment and follow-up. Annals of Oncol. 2010, 21 (Supplement 5): 223-227. 10.1093/annonc/mdq192.View ArticleGoogle Scholar
- Scherübl H, Jensen RT, Cadiot G: Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc. 2011, 3 (7): 133-139. 10.4253/wjge.v3.i7.133.View ArticlePubMedPubMed CentralGoogle Scholar
- Modlin IM, Moss SF, Oberg K, Padbury R, Hicks RJ, Gustafsson BI, Wright NA, Kidd M: Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. MJA. 2010, 1: 193-Google Scholar
- Burke AP, Sobin LH, Federspiel BH, Shekitka KM, Helwig EB: A clinicopathologic study of 99 cases. Arch Pathol Lab Med. 1990, 114: 700-4.PubMedGoogle Scholar
- Soga J: Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer. 2005, 103: 1587-1595. 10.1002/cncr.20939.View ArticlePubMedGoogle Scholar
- Rorstad O: Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005, 89: 151-160. 10.1002/jso.20179.View ArticlePubMedGoogle Scholar
- Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26: 3063-3072. 10.1200/JCO.2007.15.4377.View ArticlePubMedGoogle Scholar
- Kim JA, Choi W, Kim CN, Moon YS, Chang SH, Lee HR: Duodenal somatostatinoma: a case report and review. Korean J of Internal Med. 2011, 1: 26-Google Scholar
- Martin RG: Malignant tumors of the small intestine. Surg Clin North Am. 1986, 66: 779-785.PubMedGoogle Scholar
- Ito H, Perez A, Brooks DC, Osteen RT, Zinner MJ, Moore FD, Ashley SW, Whang EE: Surgical treatment of small bowel cancer: a 20-year single institution experience. J Gastrointest Surg. 2003, 7: 925-930. 10.1007/s11605-003-0042-8.View ArticlePubMedGoogle Scholar
- Czaykowski P, Hui D: Chemotheraphy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol). 2007, 19: 143-149. 10.1016/j.clon.2006.12.001.View ArticleGoogle Scholar
- Kaklamanos IG, Bathe OF, Franceschi D, Camarda C, Levi J, Livingstone AS: Extent of resection in the management of duodenal adenocarcinoma. Am J Surg. 2000, 179: 37-41. 10.1016/S0002-9610(99)00269-X.View ArticlePubMedGoogle Scholar
- Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J: Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004, 101: 518-526. 10.1002/cncr.20404.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.